Breaking News

Elan Sells Remaining Alkermes Stake

February 1, 2013

Will no longer own shares of the former EDT business

Elan Corp., through its wholly-owned subsidiary, Elan Science Three Ltd., agreed to sell its remaining 7,750,000 shares of Alkermes plc. The sale is expected to close on February 6, 2013.
 
In September 2011, Elan’s Drug Technology (EDT) business was combined with Alkermes, and Elan received 31,900,000 shares in the newly created Alkermes. In March 2012, Elan sold 24,150,000 shares of Alkermes in a public offering. After the closing, Elan will no longer own any shares of Alkermes.

Alkermes Contract Pharma Services, part of Alkermes plc, provides product development scale-up and manufacturing services to the pharmaceutical market.

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems